目的观察普米克令舒和博利康尼联合雾化吸入对慢性阻塞性肺病(COPD)急性加重期的临床疗效。方法58例COPD急性加重期住院患者随机分为两组:观察组30例给予普米克令舒1mg和博利康尼雾化液5mg联合雾化吸入治疗,2次/d;对照组28例给予博利康尼雾化液5mg雾化吸入,地塞米松10mg/d静脉滴注。记录两组患者用药7d前后PaO2、PaCO2、FEV1变化,同时观察不良反应及疗效分析。结果观察组总有效率86.67%,对照组总有效率89.29%,两组疗效相比差异无统计学意义(P>0.05);两组患者治疗前后PaO2、PaCO2、FEV1均有改善,治疗前后相比差异有统计学意义(P<0.05),但两组间相互比较差异无统计学意义(P>0.05);观察组不良反应明显少于对照组。结论普米克令舒和博利康尼联合雾化吸入能够改善COPD急性加重期患者肺功能及临床症状,与全身使用糖皮质激素疗效相近,但不良反应明显减少。 Objective To observe the clinical efficacy of pulmicort and boryl in combination with inhalation on acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods Fifty-eight inpatients with acute exacerbation of COPD were randomly divided into two groups: 30 cases in the observation group were treated with Pulmicort respules 1mg and Boli Kang Ni aerosol 5mg combined with atomized inhalation 2 times / d; control group, 28 cases were given Boli Kang Nebulizer 5mg atomized inhalation, dexamethasone 10mg / d intravenous infusion. PaO2, PaCO2 and FEV1 changes were recorded before and after treatment for 7 days in both groups. Adverse reactions and curative effects were also observed. Results The total effective rate was 86.67% in the observation group and 89.29% in the control group, there was no significant difference between the two groups (P> 0.05). PaO2, PaCO2 and FEV1 were improved in both groups before and after treatment (P <0.05), but there was no significant difference between the two groups (P> 0.05). The adverse reactions in the observation group were significantly less than those in the control group. Conclusions Combination of Pulmicort respules with boliconi combined with inhalation can improve pulmonary function and clinical symptoms in patients with acute exacerbation of COPD. The efficacy of systemic administration of glucocorticoid is similar, but adverse reactions are significantly reduced.